PBAC's latest decision on Tirzepatide: Recommended with restriction (2025). Considered for Treatment of adults with type 2 diabetes mellitus that is inadequately controlled despite use of metformin, sulfonylurea, and/or insulin, or in patients with contraindication or intolerance to SGLT2 inhibitors.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
$30k/QALY
$30k/QALY–— · across 2 submissions
Submissions
3
first 2023
Submissions
3
2023 → 2025
Eligible population
Adult patients with type 2 diabetes with BMI ≥35 kg/m² or who identify as Aboriginal and Torres Strait Islander peoples who are contraindicated, intolerant or inadequately controlled with SGLT2 inhibitors.
Therapy area
Endocrinology
Line of therapy
Later-line
Evidence base
RCT
Primary endpoint
QoL
Key trials
SURPASS-2
Comparator
semaglutide
Economic model
CUA
ICER note
ICER of approximately $30,000 per QALY achieved for tirzepatide 10 mg versus semaglutide 1 mg and tirzepatide 15 mg versus semaglutide 1 mg through price reduction. The ICER for tirzepatide 5 mg versus semaglutide 1 mg remained substantially higher than recommended.
ICER basis
Range aggregates 2 submissions (2024–2025) — not a single base case.
Risk sharing
Risk-sharing arrangement in place — Risk sharing arrangement consisting of a subsidisation cap with use beyond the nominated caps rebated to government.
Submission history
Jul 2023: Recommended with restriction · Authority Required
Nov 2024: Recommended with restriction · Authority Required — ICER $45k/QALY